

### Company Overview

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers. We have three core technologies, all of which are based on discoveries made at M.D. Anderson Cancer Center by Dr. Waldemar Priebe and his team. Our clinical stage drugs are Annamycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors.

Our Next Generation Anthracycline, Annamycin, is unlike any currently approved anthracyclines, as it is designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin has preliminary clinical data suggesting its potential to become the first successful therapy suitable for the majority of relapsed or refractory AML patients and is currently in two Phase I/II clinical trials.

WP1066 is one of several Immune/Transcription Modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1 $\alpha$ . These transcription factors are widely sought targets that may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors.

We are also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis. Our lead Metabolism/Glycosylation Inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy (2-DG) within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.

### Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

Nov 13 2019, 7:30 AM EST

### Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

Nov 12 2019, 8:00 AM EST

### Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019

Nov 12 2019, 7:00 AM EST

### Stock Overview

Symbol  
Exchange  
Market Cap  
Last Price  
52-Week

MBRX  
Nasdaq  
\$  
\$ - \$

### Investor Relations

Lytham Partners, LLC  
Joe Dorame  
Managing Partner  
T: (602) 889-9700

### Management Team

#### Walter V. Klemp

Founder, President, Chairman, CEO, and Business Advisory Board Member

#### Donald Picker, PhD

Chief Scientific Officer

#### Robert Shepard, MD, FACP

Chief Medical Officer - Hematology

#### Sandra Silberman, MD, PhD

Chief Medical Officer - New Products

#### Jonathan P. Foster

Chief Financial Officer

### Moleculin Biotech, Inc.

5300 Memorial Drive  
Suite 950  
Houston, TX 77007

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.